Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis

Molecular Neurobiology

Volumn 55, Issue 5, 2018, Pages 4195-4206

  Köhler, Cristiano A ^a   Freitas, Thiago H ^a   Stubbs, Brendon ^b,c   Maes, Michael ^d,e,f,g,h   Solmi, Marco ^i,j   Veronese, Nicola ^j,k   de Andrade, Nayanna Q ^a   Morris, Gerwyn ^d   Fernandes, Brisa S ^d,l   Brunoni, André R ^m   Herrmann, Nathan ^n,o   Raison, Charles L ^p,q   Miller, Brian J ^r   Lanctôt, Krista L ^n,o   Carvalho, André F ^a,s  

^a Faculty of Medicine   (Brazil)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d DEAKIN UNIVERSITY   (Australia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f STATE UNIVERSITY OF LONDRINA   (Brazil)

^g MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^h Revitalis   (Netherlands)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Institute of Clinical Research and Education in Medicine (IREM)   (Italy)

^k CNR   (Italy)

^l FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

ⁿ Canada   (Canada)

^o UNIVERSITY OF TORONTO   (Canada)

^p UNIVERSITY OF WISCONSIN MADISON   (United States)

^q UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^r MEDICAL COLLEGE OF GEORGIA   (United States)

^s FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

more..

Author keywords

Antidepressant; Chemokines; Cytokines; Depression; Inflammation; Meta analysis

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR; ANTIDEPRESSANT AGENT; CHEMOKINE;

CLINICAL EFFECTIVENESS; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; MAJOR DEPRESSION; MENTAL DISEASE ASSESSMENT; META ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; METABOLISM;

ANTIDEPRESSIVE AGENTS; CHEMOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; TREATMENT OUTCOME;

EID: 85020741434     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-017-0632-1     Document Type: Review

References (57)

1. Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16(1):22–34. doi:10.1038/nri.2015.5
2. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46–56. doi:10.1038/nrn2297
3. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785. doi:10.1016/j.neubiorev.2011.12.005
4. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27(1):24–31. doi:10.1016/j.it.2005.11.006
5. Stuart MJ, Baune BT (2014) Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 42:93–115. doi:10.1016/j.neubiorev.2014.02.001
6. Kohler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctot KL, Carvalho AF (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. doi:10.1111/acps.12698
7. Li X, Frye MA, Shelton RC (2012) Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 37(1):77–101. doi:10.1038/npp.2011.198
8. Leonard BE (2014) Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 48:261–267. doi:10.1016/j.pnpbp.2013.10.018
9. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR (2012) A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 26(3):469–479. doi:10.1016/j.bbi.2011.12.011
10. Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 36(12):2452–2459. doi:10.1038/npp.2011.132
11. Hiles SA, Baker AL, de Malmanche T, Attia J (2012) Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 42(10):2015–2026. doi:10.1017/s0033291712000128
12. Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord 148(1):136–140. doi:10.1016/j.jad.2012.10.036
13. Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M (2013) Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord 145(3):300–307. doi:10.1016/j.jad.2012.08.007
14. Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, Pariante CM (2016) Absolute measurements of macrophage migration inhibitory factor and interleukin-1-beta mRNA levels accurately predict treatment response in depressed patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). doi:10.1093/ijnp/pyw045
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 339:b2700. doi:10.1136/bmj.b2700
16. Bakkalbasi N, Bauer K, Glover J, Wang L (2006) Three options for citation tracking: Google Scholar, Scopus and Web of Science. Biomedical digital libraries 3:7. doi:10.1186/1742-5581-3-7
17. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn (DSM-5), 5th edn. American Psychiatric Association
18. World Health Organization (1993) The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization, Geneva
19. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. doi:10.1186/1471-2288-5-13
20. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826
21. Patsopoulos NA, Evangelou E, Ioannidis JP (2009) Heterogeneous views on heterogeneity. Int J Epidemiol 38(6):1740–1742. doi:10.1093/ije/dyn235
22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
23. Cohen J (1992) A power primer. Psychol Bull 112(1):155–159
24. Carvalho AF, Kohler CA, Fernandes BS, Quevedo J, Miskowiak KW, Brunoni AR, Machado-Vieira R, Maes M et al (2016) Bias in emerging biomarkers for bipolar disorder. Psychol Med 46(11):2287–2297. doi:10.1017/s0033291716000957
25. Carvalho AF, Kohler CA, Brunoni AR, Miskowiak KW, Herrmann N, Lanctot KL, Hyphantis TN, Quevedo J et al (2016) Bias in peripheral depression biomarkers. Psychother Psychosom 85(2):81–90. doi:10.1159/000441457
26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 315(7109):629–634
27. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463
28. Rosenthal R (1979) The file drawer problem and tolerance for null results. Psychol Bull 86(3):638
29. Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559–1573. doi:10.1002/sim.1187
30. Hernandez ME, Mendieta D, Martinez-Fong D, Loria F, Moreno J, Estrada I, Bojalil R, Pavon L (2008) Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 18(12):917–924. doi:10.1016/j.euroneuro.2008.08.001
31. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 25(10):1532–1543. doi:10.1016/j.euroneuro.2015.06.007
32. Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709. doi:10.1038/mp.2016.3
33. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M (2015) Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206–215. doi:10.1016/j.bbi.2015.06.001
34. Eyre HA, Air T, Pradhan A, Johnston J, Lavretsky H, Stuart MJ, Baune BT (2016) A meta-analysis of chemokines in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 68:1–8. doi:10.1016/j.pnpbp.2016.02.006
35. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167(11):1305–1320. doi:10.1176/appi.ajp.2009.10030434
36. Riazi K, Galic MA, Kentner AC (2015) Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation. 35(12):4942–4952. doi:10.1523/jneurosci.4485-14.2015
37. Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37(9):1397–1416. doi:10.1016/j.psyneuen.2012.03.019
38. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA psychiatry 70(1):31–41. doi:10.1001/2013.jamapsychiatry.4
39. Miller AH, Haroon E, Felger JC (2016) Therapeutic implications of brain-immune interactions: treatment in translation. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. doi:10.1038/npp.2016.167
40. Wohleb ES, Delpech JC (2016) Dynamic cross-talk between microglia and peripheral monocytes underlies stress-induced neuroinflammation and behavioral consequences. Prog Neuro-Psychopharmacol Biol Psychiatry. doi:10.1016/j.pnpbp.2016.04.013
41. Mills CD (2015) Anatomy of a discovery: m1 and m2 macrophages. Front Immunol 6:212. doi:10.3389/fimmu.2015.00212
42. Durairaj H, Steury MD, Parameswaran N (2015) Paroxetine differentially modulates LPS-induced TNFalpha and IL-6 production in mouse macrophages. Int Immunopharmacol 25(2):485–492. doi:10.1016/j.intimp.2015.02.029
43. Ge S, Song L, Serwanski DR, Kuziel WA, Pachter JS (2008) Transcellular transport of CCL2 across brain microvascular endothelial cells. J Neurochem 104(5):1219–1232. doi:10.1111/j.1471-4159.2007.05056.x
44. Wohleb ES, Franklin T, Iwata M, Duman RS (2016) Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci 17(8):497–511. doi:10.1038/nrn.2016.69
45. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10(7):490–500. doi:10.1038/nri2785
46. Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B (2012) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10:66. doi:10.1186/1741-7015-10-66
47. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, Henigsberg N, Souery D et al (2009) Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord 118(1–3):147–154. doi:10.1016/j.jad.2009.02.013
48. Orenes-Pinero E, Pineda J, Roldan V, Hernandez-Romero D, Marco P, Tello-Montoliu A, Sogorb F, Valdes M et al (2015) Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and prothrombotic state. J Atheroscler Thromb 22(6):610–617. doi:10.5551/jat.26161
49. Slyepchenko A, Brunoni AR, McIntyre RS, Quevedo J, Carvalho AF (2016) The adverse effects of smoking on health outcomes in bipolar disorder: a review and synthesis of biological mechanisms. Curr Mol Med 16(2):187–205
50. Liu CS, Carvalho AF, McIntyre RS (2014) Towards a “metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS & neurological disorders drug targets 13(10):1693–1707
51. Slyepchenko A, Maes M, Machado-Vieira R, Anderson G, Solmi M, Sanz Y, Berk M, Kohler CA et al (2016) Intestinal dysbiosis, gut hyperpermeability and bacterial translocation: missing links between depression, obesity and type 2 diabetes. Curr Pharm Des 22(40):6087–6106
52. Slyepchenko A, Maes M, Jacka FN, Kohler CA, Barichello T, McIntyre RS, Berk M, Grande I et al (2017) Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother Psychosom 86(1):31–46. doi:10.1159/000448957
53. Gold PW (2015) The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry 20(1):32–47. doi:10.1038/mp.2014.163
54. Eller T, Vasar V, Shlik J, Maron E (2009) The role of IL-2 and soluble IL-2R in depression and antidepressant response. Current opinion in investigational drugs (London, England: 2000) 10(7):638–643
55. Jarventausta K, Sorri A, Kampman O, Bjorkqvist M, Tuohimaa K, Hamalainen M, Moilanen E, Leinonen E et al (2017) Changes in interleukin-6 levels during electroconvulsive therapy may reflect the therapeutic response in major depression. Acta Psychiatr Scand 135(1):87–92. doi:10.1111/acps.12665
56. Guloksuz S, Rutten BP, Arts B, van Os J, Kenis G (2014) The immune system and electroconvulsive therapy for depression. The journal of ECT 30(2):132–137. doi:10.1097/yct.0000000000000127
57. Fernandes BS, Williams LM, Steiner J, Leboyer M, Carvalho AF, Berk M (2017) The new field of ‘precision psychiatry’. BMC Med 15(1):80. doi:10.1186/s12916-017-0849-x